1.Current Status and Strategic Recommendations for Randomized Controlled Trials on Functional Dyspepsia-Irritable Bowel Syndrome Comorbidity:from a Real-World Research Perspective
Ning DAI ; Linlin JIANG ; Huie ZHANG ; Fang LU
Journal of Traditional Chinese Medicine 2026;67(9):946-950
By analyzing the current status of randomized controlled trials (RCTs) on functional dyspepsia (FD) and irritable bowel syndrome (IBS) comorbidity, we identified several critical issues which include insufficient repor-ting of FD and IBS subtypes, inadequate risk assessment of drug combination, lack of composite, objective, and long-term outcomes, and weak evidence support for clinical practice guidelines. It is suggested that future clinical research on FD-IBS comorbidity should further strengthen the application of real-world studies. The use of composite outcomes and long-term follow-up is recommended to improve the quality of evidence, while greater attention should be paid to patients' preferences and self-management to enhance the applicability of findings. Based on the existing issues in clinical studies of traditional Chinese medicine (TCM) for FD-IBS comorbidity, we propose to consolidate the foundation of TCM-specific efficacy evaluation to better reflect the advantages of syndrome differentiation and treatment, optimize real-world study designs to better support clinical decision- making, and introduce intelligent objective evaluation technologies to improve the objectivity and accuracy of TCM clinical efficacy assessment.
2.Current Status and Strategic Recommendations for Randomized Controlled Trials on Functional Dyspepsia-Irritable Bowel Syndrome Comorbidity:from a Real-World Research Perspective
Ning DAI ; Linlin JIANG ; Huie ZHANG ; Fang LU
Journal of Traditional Chinese Medicine 2026;67(9):946-950
By analyzing the current status of randomized controlled trials (RCTs) on functional dyspepsia (FD) and irritable bowel syndrome (IBS) comorbidity, we identified several critical issues which include insufficient repor-ting of FD and IBS subtypes, inadequate risk assessment of drug combination, lack of composite, objective, and long-term outcomes, and weak evidence support for clinical practice guidelines. It is suggested that future clinical research on FD-IBS comorbidity should further strengthen the application of real-world studies. The use of composite outcomes and long-term follow-up is recommended to improve the quality of evidence, while greater attention should be paid to patients' preferences and self-management to enhance the applicability of findings. Based on the existing issues in clinical studies of traditional Chinese medicine (TCM) for FD-IBS comorbidity, we propose to consolidate the foundation of TCM-specific efficacy evaluation to better reflect the advantages of syndrome differentiation and treatment, optimize real-world study designs to better support clinical decision- making, and introduce intelligent objective evaluation technologies to improve the objectivity and accuracy of TCM clinical efficacy assessment.
3.Mechanism of Yizhi Qingxin Prescription in Regulating PKA/CaN Pathway to Improve Cognitive Function in Alzheimer's Disease Model Mice
Xiaochen GUO ; Jiangang LIU ; Dandan SHI ; Ziqi NING ; Yaoyao ZHANG ; Fang LIU ; Meixia LIU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(3):97-108
ObjectiveTo explore the mechanism by which Yizhi Qingxin prescription improves mitochondrial dysfunction in Alzheimer's disease (AD) through regulating mitochondrial Ca2+ homeostasis and kinetic balance based on the protein kinase A (PKA)/calcineurin (CaN) signaling pathway. MethodsSixty three-month-old amyloid precursor protein (APP)/presenilin 1 (PS1) double transgenic mice were randomly divided into a model group, a donepezil group(0.65 mg·kg-1), a low-dose Yizhi Qingxin prescription group (YQF-L,2.6 g·kg-1), a medium-dose Yizhi Qingxin prescription group (YQF-M,5.2 g·kg-1), and a high-dose Yizhi Qingxin prescription group (YQF-H,10.4 g·kg-1), with 12 mice in each group. Twelve C57BL/6J mice with the same genetic background served as a normal group. Each treatment group received gavage administration daily, with the model and normal groups receiving equal volume of physiological saline. Intervention continued for 12 consecutive weeks. The learning and memory abilities of the mice were assessed using the novel object recognition (NOR) and Morris water maze (MWM) tests. Hematoxylin-eosin (HE)/Nissl staining was used to observe histopathological changes in the hippocampus. Transmission electron microscopy (TEM) was used to observe mitochondrial ultrastructure. Fluo-4 acetoxymethyl ester (Fluo-4 AM) Ca2+ probe was used to measure intracellular Ca2+ concentration in brain tissue. Western blot was used to determine the protein expression of PKA, CaN, sodium/calcium/lithium exchanger (NCLX), mitochondrial calcium uniporter (MCU), calmodulin (CaM), dynamin-related protein 1 (Drp1), and phosphorylated dynamin-related protein 1 (serine 637 site) [p-Drp1(S637)] in the hippocampus. Real-time quantitative polymerase chain reaction (Real-time PCR) was used to measure the expression of PKA, CaN, CaM, NCLX, MCU, and Drp1 mRNAs. ResultsCompared with those in the normal group, the recognition index (RI) of the model group decreased (P0.01), and the number of crossings through the original platform area, the duration of stay in the target quadrant, and the distance were reduced (P0.01). The protein expression of PKA, NCLX, and p-DRP1 (ser637) significantly decreased (P0.05), and the mRNA expression of PKA and NCLX significantly decreased (P0.05). The escape latency (EL) was prolonged (P0.05), and the intracellular Ca2+ level significantly increased (P0.01). The protein expression of CaN, CaM, MCU, and Drp1, as well as the mRNA expression of CaN, MCU, and Drp1, significantly increased (P0.05). After intervention with Donepezil and Yizhi Qingxin prescription, compared with that in the model group, the RI of the treatment group significantly increased (P0.05), and the number of crossings through the platform and the duration of stay in the target quadrant significantly increased (P0.05). The protein expression of PKA, NCLX, and p-Drp1 (ser637) and the mRNA expression of PKA and NCLX significantly increased (P0.05). On the 4th and 5th days, the EL was shortened (P0.05), and the intracellular Ca2+ level decreased (P0.05). The protein expression of CaN, CaM, MCU, and Drp1 and the mRNA expression of CaN, MCU, and Drp1 significantly decreased (P0.05). ConclusionYizhi Qingxin prescription regulates the PKA/CaN pathway, upregulates the expression of PKA, NCLX, and p-Drp1 (ser637) proteins, reduces the expression of CaN, CaM, MCU, and Drp1 proteins, and regulates Ca2+ homeostasis and mitochondrial dynamic balance, thereby enhancing the spatial learning and memory abilities of AD mice.
4.Mechanism of Yizhi Qingxin Prescription in Regulating PKA/CaN Pathway to Improve Cognitive Function in Alzheimer's Disease Model Mice
Xiaochen GUO ; Jiangang LIU ; Dandan SHI ; Ziqi NING ; Yaoyao ZHANG ; Fang LIU ; Meixia LIU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(3):97-108
ObjectiveTo explore the mechanism by which Yizhi Qingxin prescription improves mitochondrial dysfunction in Alzheimer's disease (AD) through regulating mitochondrial Ca2+ homeostasis and kinetic balance based on the protein kinase A (PKA)/calcineurin (CaN) signaling pathway. MethodsSixty three-month-old amyloid precursor protein (APP)/presenilin 1 (PS1) double transgenic mice were randomly divided into a model group, a donepezil group(0.65 mg·kg-1), a low-dose Yizhi Qingxin prescription group (YQF-L,2.6 g·kg-1), a medium-dose Yizhi Qingxin prescription group (YQF-M,5.2 g·kg-1), and a high-dose Yizhi Qingxin prescription group (YQF-H,10.4 g·kg-1), with 12 mice in each group. Twelve C57BL/6J mice with the same genetic background served as a normal group. Each treatment group received gavage administration daily, with the model and normal groups receiving equal volume of physiological saline. Intervention continued for 12 consecutive weeks. The learning and memory abilities of the mice were assessed using the novel object recognition (NOR) and Morris water maze (MWM) tests. Hematoxylin-eosin (HE)/Nissl staining was used to observe histopathological changes in the hippocampus. Transmission electron microscopy (TEM) was used to observe mitochondrial ultrastructure. Fluo-4 acetoxymethyl ester (Fluo-4 AM) Ca2+ probe was used to measure intracellular Ca2+ concentration in brain tissue. Western blot was used to determine the protein expression of PKA, CaN, sodium/calcium/lithium exchanger (NCLX), mitochondrial calcium uniporter (MCU), calmodulin (CaM), dynamin-related protein 1 (Drp1), and phosphorylated dynamin-related protein 1 (serine 637 site) [p-Drp1(S637)] in the hippocampus. Real-time quantitative polymerase chain reaction (Real-time PCR) was used to measure the expression of PKA, CaN, CaM, NCLX, MCU, and Drp1 mRNAs. ResultsCompared with those in the normal group, the recognition index (RI) of the model group decreased (P0.01), and the number of crossings through the original platform area, the duration of stay in the target quadrant, and the distance were reduced (P0.01). The protein expression of PKA, NCLX, and p-DRP1 (ser637) significantly decreased (P0.05), and the mRNA expression of PKA and NCLX significantly decreased (P0.05). The escape latency (EL) was prolonged (P0.05), and the intracellular Ca2+ level significantly increased (P0.01). The protein expression of CaN, CaM, MCU, and Drp1, as well as the mRNA expression of CaN, MCU, and Drp1, significantly increased (P0.05). After intervention with Donepezil and Yizhi Qingxin prescription, compared with that in the model group, the RI of the treatment group significantly increased (P0.05), and the number of crossings through the platform and the duration of stay in the target quadrant significantly increased (P0.05). The protein expression of PKA, NCLX, and p-Drp1 (ser637) and the mRNA expression of PKA and NCLX significantly increased (P0.05). On the 4th and 5th days, the EL was shortened (P0.05), and the intracellular Ca2+ level decreased (P0.05). The protein expression of CaN, CaM, MCU, and Drp1 and the mRNA expression of CaN, MCU, and Drp1 significantly decreased (P0.05). ConclusionYizhi Qingxin prescription regulates the PKA/CaN pathway, upregulates the expression of PKA, NCLX, and p-Drp1 (ser637) proteins, reduces the expression of CaN, CaM, MCU, and Drp1 proteins, and regulates Ca2+ homeostasis and mitochondrial dynamic balance, thereby enhancing the spatial learning and memory abilities of AD mice.
5.Effect and mechanism of peroxiredoxin 1 in microglial inflammation after spinal cord injury
Yongcheng YIN ; Xiangrui ZHAO ; Zhijie YANG ; Zheng LI ; Fang LI ; Bin NING
Chinese Journal of Tissue Engineering Research 2026;30(5):1106-1113
BACKGROUND:The inflammatory response of microglia is closely related to neuronal survival,regeneration,and functional recovery after spinal cord injury.Peroxiredoxin 1 is not only involved in the regulation of oxidative stress,but also has an important effect on cell proliferation,apoptosis,and inflammatory response.OBJECTIVE:To investigate the role and mechanism of peroxiredoxin 1 in the inflammatory response of microglia following spinal cord injury.METHODS:(1)Twelve female C57BL/6 mice were randomly divided into sham-operated(n=6)and spinal cord injury(n=6)groups.The sham-operated group was not modeled and acute spinal cord injury models were constructed in the spinal cord injury group using the modified Allen's method.Spinal cord tissue at the injured site was taken at 7 days after modeling and transcriptome sequencing was performed to identify differentially expressed genes.The expression of peroxiredoxin 1 in spinal cord tissues was verified using western blot and RT-qPCR.(2)Mouse microglia BV2 were divided into two groups:the control group was stimulated with lipopolysaccharide for 6 hours,and in the knockout group,lipopolysaccharide stimulation was applied for 6 hours at 24 hours after peroxiredoxin 1 was knocked down in the cells.RT-qPCR was performed to detect mRNA expression of peroxiredoxin 1,inflammatory factors(interleukin 1β,interleukin 6,inducible nitric oxide synthase,tumor necrosis factor α,C-C motif chemokine ligand 2,and C-X-C motif chemokine ligand 2),and western blot was performed to detect the expression of peroxiredoxin 1,inducible nitric oxide synthase,and reactive oxygen/mitogen-activated protein kinase signaling pathway proteins.Mouse microglia BV2 were treated in two groups:the control group was stimulated by hydrogen peroxide for 4 hours,and the knockout group was stimulated by hydrogen peroxide for 4 hours at 24 hours after knockdown of peroxiredoxin 1.The level of reactive oxygen species was detected by 2,7-dichlorodihydrofluorescein diacetate probe.RESULTS AND CONCLUSION:(1)Results from transcriptome sequencing,western blot and RT-qPCR confirmed that peroxiredoxin 1 expression levels in mouse spinal cord tissues were significantly higher in the spinal cord injury group than the sham-operated group(P<0.05).(2)Peroxiredoxin 1 knockdown in microglial cells led to decreased expression of peroxiredoxin 1 mRNA and protein(P<0.05),increased mRNA expression of interleukin 1β,interleukin 6,inducible nitric oxide synthase,tumor necrosis factor α,C-C motif chemokine ligand 2,and C-X-C motif chemokine ligand 2(P<0.05),increased protein expression of inducible nitric oxide synthase,P-P38,P-JNK and P-ERK proteins(P<0.05),and increased level of reactive oxygen species(P<0.05).To conclude,peroxiredoxin 1 regulates microglial inflammation by targeting the reactive oxygen species/mitogen-activated protein kinase signaling pathway.
6.Effect and mechanism of peroxiredoxin 1 in microglial inflammation after spinal cord injury
Yongcheng YIN ; Xiangrui ZHAO ; Zhijie YANG ; Zheng LI ; Fang LI ; Bin NING
Chinese Journal of Tissue Engineering Research 2026;30(5):1106-1113
BACKGROUND:The inflammatory response of microglia is closely related to neuronal survival,regeneration,and functional recovery after spinal cord injury.Peroxiredoxin 1 is not only involved in the regulation of oxidative stress,but also has an important effect on cell proliferation,apoptosis,and inflammatory response.OBJECTIVE:To investigate the role and mechanism of peroxiredoxin 1 in the inflammatory response of microglia following spinal cord injury.METHODS:(1)Twelve female C57BL/6 mice were randomly divided into sham-operated(n=6)and spinal cord injury(n=6)groups.The sham-operated group was not modeled and acute spinal cord injury models were constructed in the spinal cord injury group using the modified Allen's method.Spinal cord tissue at the injured site was taken at 7 days after modeling and transcriptome sequencing was performed to identify differentially expressed genes.The expression of peroxiredoxin 1 in spinal cord tissues was verified using western blot and RT-qPCR.(2)Mouse microglia BV2 were divided into two groups:the control group was stimulated with lipopolysaccharide for 6 hours,and in the knockout group,lipopolysaccharide stimulation was applied for 6 hours at 24 hours after peroxiredoxin 1 was knocked down in the cells.RT-qPCR was performed to detect mRNA expression of peroxiredoxin 1,inflammatory factors(interleukin 1β,interleukin 6,inducible nitric oxide synthase,tumor necrosis factor α,C-C motif chemokine ligand 2,and C-X-C motif chemokine ligand 2),and western blot was performed to detect the expression of peroxiredoxin 1,inducible nitric oxide synthase,and reactive oxygen/mitogen-activated protein kinase signaling pathway proteins.Mouse microglia BV2 were treated in two groups:the control group was stimulated by hydrogen peroxide for 4 hours,and the knockout group was stimulated by hydrogen peroxide for 4 hours at 24 hours after knockdown of peroxiredoxin 1.The level of reactive oxygen species was detected by 2,7-dichlorodihydrofluorescein diacetate probe.RESULTS AND CONCLUSION:(1)Results from transcriptome sequencing,western blot and RT-qPCR confirmed that peroxiredoxin 1 expression levels in mouse spinal cord tissues were significantly higher in the spinal cord injury group than the sham-operated group(P<0.05).(2)Peroxiredoxin 1 knockdown in microglial cells led to decreased expression of peroxiredoxin 1 mRNA and protein(P<0.05),increased mRNA expression of interleukin 1β,interleukin 6,inducible nitric oxide synthase,tumor necrosis factor α,C-C motif chemokine ligand 2,and C-X-C motif chemokine ligand 2(P<0.05),increased protein expression of inducible nitric oxide synthase,P-P38,P-JNK and P-ERK proteins(P<0.05),and increased level of reactive oxygen species(P<0.05).To conclude,peroxiredoxin 1 regulates microglial inflammation by targeting the reactive oxygen species/mitogen-activated protein kinase signaling pathway.
7.Association study of SLC7A11 gene polymorphisms with helicobacter pylori infection and non-cardia gastric cancer
Linli WANG ; Fang GAO ; Wenjie DONG ; Ning CHU ; Yanbin JIA
Acta Universitatis Medicinalis Anhui 2026;61(6):1124-1129
ObjectiveTo explore the correlation between the polymorphisms of the solute carrier family7 member11 (SLC7A11) gene and the risk of non-cardia gastric cancer (NCGC) as well as the infection of Helicobacter pylori (H.pylori). MethodsA total of 435 patients with NCGC and 479 healthy individuals undergoing physical examinations were included. The polymorphisms of the SLC7A11 gene (rs7674870, rs11734488, rs12506138, rs10022036) were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The influence of each locus on H. pylori infection and the occurrence of NCGC was analyzed. ResultsNo significant associations were found among SNP rs7674870, rs11734488, and rs12506138 and H. pylori infection (P>0.05). The CT genotype and CC genotype of rs12506138, when in a codominant model, reduced the risk of developing NCGC compared to the TT genotype; the A-C-C and A-T-C haplotypes constructed by SLC7A11 rs7674870, rs11734488, rs12506138 were associated with a reduced risk of NCGC; the A-T-T and G-C-C haplotypes were associated with an increased risk of NCGC. ConclusionSLC7A11 rs7674870 and rs11734488 are not pivotal genetic loci for H. pylori infection and the pathogenesis of NCGC. SLC7A11 rs12506138 acts as a protective genetic locus for NCGC and antagonizes its oncogenic progression. The haplotype composed of the above three loci participates in regulating the overall genetic susceptibility to NCGC.
8.PPARα activation alleviates lithocholic acid-induced liver injury by inhibiting pyroptosis
Hang-Fei Liang ; Chuo-Ying Mai ; Xuan Li ; Jia-Ning Tian ; Hai-Guo Su ; Min Huang ; Jian-Hong Fang ; Hai-Tao Wang ; Xiao Yang ; Hui-Chang Bi
Liver Research 2026;10(2):177-188
Background and aims
The mechanism of cholestatic liver injury (CLI) is unclear, and effective therapies are lacking. While peroxisome proliferator-activated receptor alpha (PPARα) agonists show potential hepatoprotective effect and pyroptosis is implicated in hepatocellular damage, how PPARα activation mitigates lithocholic acid (LCA)-induced pyroptosis remains unknown.
Methods
The hepatoprotective effect of PPARα agonists was evaluated in a mouse model of intrahepatic cholestasis induced by LCA. Liver injury was assessed via serum biochemistry, hematoxylin and eosin and TUNEL staining, and electron microscopy. Pyroptosis pathways were analyzed using real-time quantitative polymerase chain reaction, Western blot, and co-immunoprecipitation.
Results
Combined morphological, histopathological, and biochemical analyses confirmed that PPARα activation protects against CLI. Compared with LCA treatment alone, PPARα activation significantly attenuated the elevation of serum lactate dehydrogenase (LDH), the increased TUNEL-positive cells, and the formation of hepatocyte membrane pores. Mechanistically, PPARα activation suppressed both NOD-like receptor protein 3 (NLRP3) inflammasome-mediated pyroptosis and apoptosis protease-activating factor-1 (APAF-1)/CASPASE-3/GSDME-mediated pyroptosis. Furthermore, PPARα agonist pretreatment inhibited activation of the nuclear factor-kappa B (NF-κB) and forkhead box O1 (FOXO1) signaling pathways.
Conclusions
PPARα protects against LCA-induced CLI by inhibiting both NLRP3 inflammasome-mediated pyroptosis associated with NF-κB and APAF-1/CASPASE-3/GSDME-mediated pyroptosis associated with the FOXO1 signaling pathway.
9.Pachymic acid inhibits proliferation and invasion of gastric cancer cells via the FOXO3-FOXM1 axis: a mechanism study
Wang Ping¹ ; ; Wang Juan² ; ᵃ ; Fang Ning² ; ᵃ ; He Yanxin² ; ᵇ ; Lu Jie³ ;
Chinese Journal of Cancer Biotherapy 2026;33(10):1047-1053
[摘 要] 目的:探究茯苓酸对胃癌AGS细胞增殖、侵袭、细胞周期及免疫相关分子水平的影响,并分析FOXO3-FOXM1轴在其中的可能作用。方法:采用CCK-8法检测不同浓度茯苓酸对胃癌AGS细胞和人永生化胃上皮细胞GES-1细胞活力的影响,并筛选后续实验浓度。将AGS细胞分为空白对照组、低-茯苓酸组、中-茯苓酸组、高-茯苓酸组、高-茯苓酸 + FOXO3敲低对照(si-NC)组、高-茯苓酸 + FOXO3敲低(si-FOXO3)组。采用集落形成实验、Transwell实验和免疫荧光法检测茯苓酸对AGS细胞增殖和侵袭能力的影响;采用PI染色流式细胞术检测细胞周期分布;Western blotting法检测Cyclin B1、CDK1、FOXO3及FOXM1蛋白的表达;ELISA检测细胞培养上清中PD-L1、MHC-Ⅰ、TGF-β1及IL-6含量。结果:茯苓酸可以浓度依赖性抑制AGS细胞的活力(IC50为40.5 μmol/L),且在10~40 μmol/L范围内,对GES-1细胞活力无明显影响。与空白对照组相比,低、中、高浓度茯苓酸组AGS细胞集落形成数、Ki-67阳性率、侵袭细胞数及MMP-9阳性率均降低,G0/G1期和S期细胞比例降低,Cyclin B1和CDK1蛋白表达水平降低;细胞培养上清中PD-L1、TGF-β1和IL-6含量降低,FOXM1蛋白表达水平降低,而 G2/M 期细胞比例、MHC-Ⅰ类分子含量及FOXO3蛋白表达均升高(均P < 0.05),且上述变化总体随茯苓酸浓度升高而更加明显。与高-茯苓酸 + si-NC组比较,高-茯苓酸 + si-FOXO3组上述变化均出现不同程度的逆转(P < 0.05)。结论:茯苓酸可在体外抑制胃癌AGS细胞增殖和侵袭,诱导G2/M期细胞周期阻滞,并影响免疫相关分子水平,其作用可能与FOXO3-FOXM1轴的调节有关。
10.Efficacy and safety of 25 Gy irradiated apheresis platelets in patients with hematological diseases: a meta-analysis
Min GAO ; Wenchao ZHAO ; Yufeng SUN ; Fang WANG ; Ning CHENG ; Li ZHAO ; Wenhua WANG
Chinese Journal of Blood Transfusion 2026;39(10):1460-1468
Objective: Patients with hematological diseases frequently require repeated platelet transfusions due to myelosuppression; however, conventional non-irradiated products are prone to causing transfusion-associated graft-versus-host disease (TA-GVHD) and immune platelet transfusion refractoriness. Whether standard-dose 25 Gy irradiation impairs platelet function or affects transfusion efficacy has long been debated. This study aimed to systematically evaluate the efficacy and safety of 25 Gy γ-ray or X-ray irradiated apheresis platelets in patients with hematological diseases, thereby providing high-level evidence for clinical transfusion practice. Methods: The China National Knowledge Infrastructure (CNKI), Wanfang Med, VIP, PubMed, and Embase databases were systematically searched from their inception to March 16, 2026. Randomized controlled trials (RCTs) and retrospective cohort studies comparing the transfusion outcomes of 25 Gy irradiated versus non-irradiated apheresis platelets were included, and subgroup analyses were performed according to leukoreduction status. Two reviewers independently conducted literature screening, data extraction, and quality assessment. The Cochrane Risk of Bias Assessment Tool (version 1.0) and the Newcastle-Ottawa Scale (NOS) were used to evaluate the quality of the included studies. Meta-analysis was performed using RevMan 5.3 and Stata 15.1 software, and the pooled relative risk (RR) with 95% confidence interval (CI) was calculated. Results: A total of 8 studies involving 33 072 platelet transfusion episodes were included, comprising 4 RCTs and 4 retrospective cohort studies. The meta-analysis revealed that, compared with nonirradiated leukoreduced apheresis platelets, the irradiated leukoreduced group showed a significantly higher 24 h transfusion efficacy rate (RR=1.12, 95% CI: 1.09-1.14, P<0.001, I
=0%). Compared with non-irradiated apheresis platelets, the irradiated group also demonstrated a significantly improved transfusion efficacy rate (RR=1.08, 95%CI: 1.03-1.13, P=0.002, I
=47%). Regarding safety, the risk of overall adverse reactions (fever and allergic reactions) in the irradiated group was reduced by 69% (RR=0.31, 95%CI: 0.13-0.75, P=0.01, I
=0%). Heterogeneity was low across all comparisons. Quantitative publication bias test was not performed due to the limited number of included studies. Conclusion: Standarddose 25 Gy irradiation does not impair, but rather significantly improves, the platelet transfusion efficacy rate while substantially reducing the risk of transfusion adverse reactions. Based on the current moderate- and low-level evidence, the "irradiation+leukoreduction" platelet transfusion strategy may be prioritized for patients with hematological diseases requiring repeated transfusions, although higher-quality studies are still needed to further validate these conclusions.


Result Analysis
Print
Save
E-mail